Asset Details
Do you wish to reserve the book?
P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest
Do you wish to request the book?
P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest
2015
Overview
Neutral sphingomyelinase-2 (nSMase2) is a ceramide-generating enzyme that has been implicated in growth arrest, apoptosis and exosome secretion. Although previous studies have reported transcriptional upregulation of nSMase2 in response to daunorubicin, through Sp1 and Sp3 transcription factors, the role of the DNA damage pathway in regulating nSMase2 remains unclear. In this study, we show that doxorubicin induces a dose-dependent induction of nSMase2 mRNA and protein with concomitant increases in nSMase activity and ceramide levels. Upregulation of nSMase2 was dependent on ATR, Chk1 and p53, thus placing it downstream of the DNA damage pathway. Moreover, overexpression of p53 was sufficient to transcriptionally induce nSMase2, without the need for DNA damage. DNA-binding mutants as well as acetylation mutants of p53 were unable to induce nSMase2, suggesting a role of nSMase2 in growth arrest. Moreover, knockdown of nSMase2 prevented doxorubicin-induced growth arrest. Finally, p53-induced nSMase2 upregulation appears to occur via a novel transcription start site upstream of exon 3. These results identify nSMase2 as a novel p53 target gene, regulated by the DNA damage pathway to induce cell growth arrest.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ 13/106
/ 13/109
/ 13/2
/ 13/31
/ 13/89
/ 38/70
/ 38/77
/ Biomedical and Life Sciences
/ Gene Expression Regulation - drug effects
/ Humans
/ Original
/ RNA, Messenger - drug effects
/ Sphingomyelin Phosphodiesterase - genetics
/ Sphingomyelin Phosphodiesterase - metabolism
/ Sphingomyelin Phosphodiesterase - physiology
/ Tumor Suppressor Protein p53 - genetics
/ Tumor Suppressor Protein p53 - metabolism
